Abstract
Erectile dysfunction is commonly defined as the inability to attain or maintain a penile erection sufficient for satisfactory sexual intercourse. The prevalence, as estimated in a cross-sectional national probability survey in the United States of America (men aged 40 years and more, May 2001–January 2002), was 22% with significant increase with aging (1). A similar prevalence of 19.2% was found in an urban area in Germany (30–80 years of age), with an increase from 2% among the youngest group to 53% in the oldest group (2). Twenty-six new cases per 1,000 men were the estimated annual incidence of erectile dysfunction determined in the Massachusetts Male Aging Study (40- to 69-year-old men) (3).
Key Points
• The majority of cases of erectile dysfunction are associated with a general vascular process including endothelial dysfunction and may be classified as vascular-type erectile dysfunction.
• Cardiovascular risk factors, such as smoking, dyslipidemia, diabetes mellitus, arterial hypertension, are very common among patients with erectile dysfunction.
• Erectile dysfunction might be an (early) harbinger of other vascular disease such as silent myocardial ischemia or cerebrovascular and peripheral arterial disease. Erectile dysfunction should initiate a cardiovascular work-up including a complete history and physical exam, an ECG, and in many cases also an exercise test. Referral to a cardiologist might be appropriate in certain patients.
• Reduction of cardiovascular risk factors, be it lifestyle change or medical intervention, should be the first step for treatment of erectile dysfunction due to vascular dysfunction.
• When cardiovascular medications, in particular antihypertensives, are prescribed, careful selection of appropriate drugs is prudent because many, in particular thiazide diuretics and β-blockers, may worsen erectile function.
• Before an appropriate treatment option is considered, patients, especially those with preexisting cardiovascular disease, should be evaluated for the issue of whether sexual intercourse can be safely recommended or whether further stabilization of the medical condition is mandatory.
• For evaluation of cardiovascular patients, recommendations of the first and second Princeton Consensus Conference may be applied.
• Oral treatment with inhibitors of phosphodiesterase-5, such as sildenafil, vardenafil, and tadalafil, is highly effective in a broad spectrum of patients presenting with erectile dysfunction.
• The use of drugs serving as nitric oxide donors, such as nitrates, is an absolute contraindication for the use of phosphodiesterase-5 inhibitors.
• A stable blood pressure (at least >90/60 mmHg) is a prerequisite for the use of phosphodiesterase-5 inhibitors. In general, concomitant use of antihypertensive therapy is well tolerated. Special caution is advisable when α(alpha)-receptor—antagonists are used simultaneously.
• Other treatment strategies, for instance testosterone replacement in hypogonadism or psychotherapy and antidepressants in major depression, are restricted to special indications and may in certain cases be combined with phosphodiesterase-5 inhibitors. Non-oral treatment strategies for erectile dysfunction, such as vacuum pumps, intracavernosal self-injection, or intraurethral application of alprostadil or penile prostheses, have become second- or third-line therapies.
• Dopamine agonists, such as sublingual apomorphine (available in Europe, but not FDA approved in the United States), are less effective than phosphodiesterase-5 inhibitors, but may be useful, in particular when contraindications do not allow use of phosphodiesterase-5 inhibitors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med. 2007;4:57–65.
Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the “Cologne Male Survey”. Int J Impot Res. 2000;12:305–311.
Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40–69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000;163:460–463.
Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med. 2000;109:3S–12S.
Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am. 1995;22:699–709.
Greiner KA, Weigel JW. Erectile dysfunction. Am Fam Physician. 1996;54:1675–1682.
Nicolosi A, Moreira E, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003;61:201–206.
NIH Consensus Development Panel on Impotence. Impotence. JAMA. 1993;270:83–90.
Nusbaum MR. Erectile dysfunction: prevalence, etiology, and major risk factors. J Am Osteopath Assoc. 2002;102: S1–S6.
McVary KT, Carrier S, Wessells H. Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America. Smoking and erectile dysfunction: evidence based analysis. J Urol. 2001;166:1624–1632.
Brock GB, Lue TF. Drug-induced male sexual dysfunction. An update. Drug Saf. 1993;8:414–446.
Keene LC, Davies PH. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev. 1999;18:5–24.
Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289:56–64.
Roth A, Kalter-Leibovici O, Kerbis Y, et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol. 2003;26:25–30.
Moulik PK, Hardy KJ. Hypertension, anti-hypertensive drug therapy and erectile dysfunction in diabetes. Diabet Med. 2003;20:290–293.
Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lance. 1985;1:181–184.
Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med. 2002;6:19–24.
Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol. 2004;43:179–184.
O’Kane PD, Jackson G. Erectile dysfunction: is there silent obstructive coronary artery disease? Int J Clin Pract. 2001;55:219–220.
Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation. 2004;110:22–26.
Billups KL. Endothelial dysfunction as a common link between erectile dysfunction and cardiovascular disease. Curr Sex Health Rep. 2004;1:137–141.
Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res. 2004;16:350–353.
Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol. 2003;170:S46–S50.
McVary KT, Carrier S, Wessells H. Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America: smoking and erectile dysfunction: evidence based analysis. J Urol. 2001;166:1624–1632.
Dorey G. Is smoking a cause of erectile dysfunction? A literature review. Br J Nurs. 2001;10:455–465.
Jeremy JY, Mikhailidis DP. Cigarette smoking and erectile dysfunction. J R Soc Health. 1998;118:151–155.
Mirone V, Imhimbo C, Bortolotti A, et al. Cigarette smoking as risk factor for erectile dysfunction: results from an Italian epidemiological study. Eur Urol. 2002;41:294–297.
Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56:302–306.
Romeo JH, Seftel AD, Madhum ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000;163:788–791.
Wassmann S, Laufs U, Bäumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:1450–1457.
Herrmann HC, Levine LA, Macaluso J, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med. 2006;3:303–308.
Carvajal A, Macias D, Sáinz M, et al. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf. 2006;29:143–149.
Ralph D, McNicholas T. Erectile Dysfunction Alliance. UK management guidelines for erectile dysfunction. BMJ. 2000;321:499–503.
Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A system review. Fam Pract. 2002;19:95–98.
Schachter M. Erectile dysfunction and lipid disorders. Curr Med Res Opin. 2000;16:S9–S12.
Carvajal A, Lérida MT, Sánchez A, Martín LH, de Diego IM. ACE inhibitors and impotence: a case series from the Spanish drug monitoring system. Drug Saf. 1995;13:130–131.
Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with lorsatan. Am J Med Sci. 2001;321:336–341.
Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006;2:447–455.
Bohlen JG, Held JP, Sanderson MO, Patterson RP. Heart rate, rate–pressure product and oxygen uptake during four sexual activities. Arch Intern Med. 1984;144:1745–1748.
Larson JL, McNaughton MW, Kennedy JW, Mansfield LW. Heart rate and blood pressure response to sexual activity and a stair-climbing test. Heart Lung. 1980;9:1025–1030.
DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol. 2000;86:175–181.
Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the second Princeton consensus conference). Am J Cardiol. 2005;96:313–321.
Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des. 2006;12: 3485–3494.
Reffelmann T, Kloner RA. Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2007;8:965–974.
Reffelmann T, Kloner RA. The cardiovascular safety of tadalafil. Expert Opin Drug Saf. 2008;7:43–52.
Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83:35C–44C.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Reffelmann, T., Kloner, R.A. (2011). Erectile Dysfunction. In: Toth, P., Cannon, C. (eds) Comprehensive Cardiovascular Medicine in the Primary Care Setting. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-963-5_21
Download citation
DOI: https://doi.org/10.1007/978-1-60327-963-5_21
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-962-8
Online ISBN: 978-1-60327-963-5
eBook Packages: MedicineMedicine (R0)